Effect of long and short half-life PDE5 inhibitors on HbA1c levels: a systematic review and meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: Phosphodiesterase 5 (PDE5) inhibitors, owing to their mechanism of action, have been gaining recognition as a potential case of drug repurposing and combination therapy for diabetes treatment.
Joseph Kim +3 more
doaj +2 more sources
Interdisciplinary MedicinePhosphodiesterase‐5 (PDE5) inhibitors are used clinically for the treatment of erectile dysfunction, pulmonary arterial hypertension, and other urological diseases.
Zhenzhan Zhang, Wangji Li
exaly +2 more sources
Data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors in instant coffee premixes [PDF]
Data in Brief, 2019 This paper presents the data on the optimisation and validation of a liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to establish the presence of phosphodiesterase 5 (PDE5) inhibitors and their analogues as adulterants in instant coffee
Ahmad Yusri Mohd Yusop +2 more
doaj +2 more sources
Improved survival with phosphodiesterase-5 inhibitor use in men with male-predominant cancers: real-world large database study [PDF]
Frontiers in OncologyIntroductionPhosphodiesterase-5 (PDE5) inhibitors, commonly prescribed for erectile dysfunction, may exhibit immunomodulatory properties by reducing myeloid-derived suppressor cell activity and enhancing T-cell responses.
Daniel Uralov +11 more
doaj +2 more sources
PDE5 inhibitor drugs for use in dementia
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment.
Atticus H. Hainsworth +4 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Multiple systematic reviews explore the effect of phosphodiesterase type 5 (PDE5) inhibitors on erectile dysfunction (ED), with each study addressing specific outcomes.
Nikolaos Pyrgidis +12 more
doaj +1 more source
Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study [PDF]
Investigative and Clinical Urology, 2021 Purpose: Phosphodiesterase type 5 (PDE5) inhibitors are effective treatments for erectile dysfunction, and several recent studies have reported positive effects of PDE5 inhibitors on semen parameters as well. However, the data are still controversial. We
Seung-Hun Song +8 more
doaj +2 more sources
Recreational Use of Phosphodiesterase 5 Inhibitors and Its Associated Factors among Undergraduate Male Students in an Ethiopian University: A Cross-Sectional Study [PDF]
The World Journal of Men's Health, 2016 Purpose: To assess the prevalence of phosphodiesterase 5 (PDE5) inhibitor use and associated factors among University of Gondar undergraduate students.
Eyob Alemayehu Gebreyohannes +5 more
doaj +1 more source
Therapeutic benefits of Phosphodiesterase type 5 inhibitors: A comprehensive review [PDF]
Archives of Pharmaceutical Sciences Ain Shams UniversityPhosphodiesterase type 5 (PDE5) inhibitors have been widely used to treat erectile dysfunction. This review aims to explore the favorable effects of PDE5 inhibitors in clinical applications beyond their conventional use.
Yasmin Nabil +3 more
doaj +1 more source
Effect of phosphodiesterase inhibitors in the bladder
Asian Journal of Urology, 2015 Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients.
Bilal Chughtai +3 more
doaj +1 more source